Telix is pleased to provide a video recording of the Company’s briefing session for shareholders held on Wednesday, June 21, 2023, at The Yale Club in New York City.

Telix today announces presentations from the Company’s investigational prostate (prostate specific-membrane antigen, or PSMA-targeting) and renal (carbonic anhydrase IX, or CAIX-targeting) diagnostic and therapeutic programs at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 Annual Meeting being held in Chicago from June 24 – 27.

Telix today provides an outline agenda for the Company’s briefing session for shareholders to be held on Wednesday, June 21, 2023, at The Yale Club in New York City, from 8.30am EDT and via live webcast (10.30pm AEST). The briefing session will provide an opportunity for shareholders to hear from the Company in relation to its recent market disclosures and will focus on:

Telix today welcomes Willy Borsus, Vice-President of Wallonia, Minister of Economy, Research and Innovation, Digital, Agriculture, Urban Planning and Regional Planning to officially open Telix Manufacturing Solutions, the Company’s radiopharmaceutical production facility located in Brussels South (Seneffe), in the Wallonia region of Belgium. Located in the heart of Belgium’s ‘Radiopharma Valley’, the 2,800 square metre facility is one of Europe’s largest radiopharmaceutical production facilities. It will serve as the Company’s primary manufacturing site for radioisotopes and commercial and clinical products for patients in the Europe Middle East and Africa (EMEA) region and beyond. Radiopharmaceuticals use targeting agents (small molecules or antibodies) to deliver targeted radiation to cancer cells, regardless of where the cancer is in the body. These agents can be used for imaging (diagnosis) or therapy. Often referred to as “theranostics”, this approach has the potential to better inform treatment decisions and deliver personalised therapy for patients. The presentation will take place on Wednesday June 7 from 12.30pm – 12.55pm EDT (2.30am – 2.55am AEST, June 8). A live webcast of the presentation will be available at the following link: https://wsw.com/webcast/jeff281/tlx/1727440 The webcast will be accessible on demand on the Telix website following the event. Institutional investors, analysts and company guests are cordially invited to attend the session, which will feature an overview of the Company's growth strategy and product pipeline for the detection and treatment of urological cancers.

Telix today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies Healthcare Conference being held in New York from June 7 to June 9, 2023. The presentation will take place on Wednesday June 7 from 12.30pm – 12.55pm EDT (2.30am – 2.55am AEST, June 8). A live webcast of the presentation will be available at the following link: https://wsw.com/webcast/jeff281/tlx/1727440 The webcast will be accessible on demand on the Telix website following the event. Institutional investors, analysts and company guests are cordially invited to attend the session, which will feature an overview of the Company's growth strategy and product pipeline for the detection and treatment of urological cancers.

Telix today announces it will host an education session for investors on Wednesday, June 21, 2023, at The Yale Club in New York City, from 8.30am – 12.30pm EDT.  Institutional investors, analysts and company guests are cordially invited to attend the session, which will feature an overview of the Company's growth strategy and product pipeline for the detection and treatment of urological cancers.

Join Telix in Adelaide, South Australia, for the 53rd Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine from the 26th to the 28th of May. We are pleased to support the premier event for nuclear medicine in Australia with a range of Telix investigational assets featured in presentations across the weekend.  Our team will be at booths #13 and #15 to share more on our approved PSMA-PET imaging agent for prostate cancer and the diagnostic and therapeutic solutions we are developing as part of our industry-leading theranostic pipeline.

Telix will showcase further detailed analyses from the Company’s completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118) will be presented in a late-breaking oral presentation at the American Urological Association (AUA) Annual Meeting being held in Chicago from 28 April to 1 May 2023.

Telix is pleased to provide a video recording of the joint webcast with Telix’s exclusive partner for the Greater China market, Grand Pharma held on 20 April 2023.

Telix Pharmaceuticals today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) to enable its use for the selection of patients with metastatic prostate cancer, for whom 177Lu 177 PSMA-directed therapy is indicated.